Bryant E. Fong

Mr. Fong joined Biomark Capital in 2013. Prior to BioMark Capital, Mr. Fong was a Managing Director and General Partner at Burrill & Company, where he spent almost 16 years investing in and managing investments in private and public companies in the biotechnology industry. Some of Mr. Fong’s recent investments include Pharmasset (VRUS), Novadaq Technologies (NVDQ), Galapagos (GLPG), Ceptaris Therapeutics (acquired by Actelion), and Ferrokin Biosciences (acquired by Shire). Prior to joining Burrill & Company, Mr. Fong held positions as a research scientist with two early-stage biotechnology companies located in the San Francisco Bay Area. Mr. Fong currently serves on the Boards of Directors of a number of life science companies including ADMA Biologics (ADMA), NEOS Therapeutics (NEOS), JHL Biotech (6540:TT), and i2Dx. Mr. Fong earned his bachelor's degree with honors in Molecular and Cell Biology-Biochemistry from the University of California, Berkeley.